Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction

Japanese Journal of Pharmacology

Volumn 75, Issue 4, 1997, Pages 311-318

  Ito, Katsuhiko ^a   Zhu, Yi Zhun ^a   Zhu, Yi Chun ^a   Gohlke, Peter ^a   Unger, Thomas ^a  

^a NONE

Author keywords

Angiotensin converting enzyme; Angiotensin II receptor antagonist; B2 receptor antagonist; Bradykinin; Cardioprotective action; Myocardial infarction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ; LOSARTAN; MOEXIPRIL; RAMIPRIL;

CAPILLARY PROLIFERATION; CORONARY ARTERY BLOOD FLOW; ENERGY METABOLISM; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; RAT; REVIEW;

EID: 0031473695     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.311     Document Type: Review

References (69)

1. Soubrier F, Alhenc-Gelas F, Hubert B, Allegrini J, John M, Tregear G and Corvol P: Two putative active centers in human angiotensin I-converting enzyme released by molecular cloning. Proc Natl Acad Sci USA 85, 9386-9390 (1988)
2. Yang HYT, Erdös EG and Levin Y: A dipeptidyl cardiopeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 214, 374-376 (1970)
3. Bhoola KD, Figueroa CD and Worthy K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44, 1-80 (1992)
4. Kaplan AP: Mechanisms of bradykinin generation in human plasma. Monogr Allergy 18, 272-276 (1983)
5. Mayfield RK and Margolius HS: Renal kallikrein-kinin system. Am J Nephrol 3, 145-155 (1983)
6. Carretero OA and Scicli AG: Kinins paracrine hormone. Kidney Int 34, Suppl 26, 52-59 (1988)
7. Müller-Esterl W, Iwanaga S and Nakanishi S: Kininogens revised. Trends Biochem Sci 11, 336-339 (1986)
8. De La Cadena AR and Colman RW: Structure and functions of human kininogens. Trends Biochem Sei 12, 272-275 (1991)
9. Frey EK, Kraut H, Werle E, Vogel R, Zickgarf-Rüdel G and Trautschold I: Das Kallikrein-Kinin-System und Seine Inhibition. F Enke, Stuttgart (1968) (in German)
10. McCarthy DA, Potter DE and Nicolaides ED: An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther 148, 117-122 (1965)
11. Barbé J, Marceau F, Thériault B, Drouin JN and Regoli D: Cardiovascular action of kinins in the rabbit. Can J Physiol Pharmacol 57, 78-91 (1979)
12. Lückhoff A, Busse R, Winter I and Basenge E: Characterization of vascular relaxant factor released from cultured endothelial cells. Hypertension 9, 295-303 (1987)
13. Busse R and Fleming I: Kinin mediated signal transduction in endothelial cells. In ACE Inhibitors, Endothelial Function and Atherosclerosis, Edited by Schölkens BA and Unger Th, pp 1-18, Media Publication, Ltd, Chicester (1993)
14. Armstrong D: Pain. Handbook Exp Pharmacol 25, 434-481 (1970)
15. Armstrong D, Jepsen JB, Keeke CS and Stewart JW: Development of pain-producing substance in human plasma. Nature 174, 791-792 (1954)
16. Hilton SM: The physiological role of glandular kallikrein. Handbook Exp Pharmacol 25, 389-399 (1970)
17. Jauch KW, Guenther B, Hartl W, Rett K, Winckmeyer M and Dietze G: Improvement of impaired postoperative insulin action by bradykinin. Biol Chem Hoppe Seyler 367, 207-210 (1986)
18. Levinsky NG: The renal kallikrein-kinin system. Circ Res 44, 441-451 (1979)
19. Nasjletti A and Malik KU: Renal kinin-prostaglandin relationship: implication for renal function. Kidney Int 19, 860-868 (1981)
20. Regoli D and Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 32, 1-46 (1980)
21. Burch RM and Kyle DJ: Recent developments in the understanding of bradykinin receptor. Life Sci 50, 829-838 (1992)
22. Hock FJ, Wirth K, Albus U, Linz W, Gerhard HJ, Wiemer G, Henke St, Breipohl G, König W, Knolle J and Schölkens BA: HOE 140 a new and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102, 769-773 (1991)
23. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke St, Breipohl G, König W, Knolle J and Schölkens BA: HOE 140 a new and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102, 774-777 (1991)
24. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P and Unger Th: HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol 200, 179-182 (1991)
25. Tomanek RJ and Hovanec JM: The effects of long-term pressure-overload and aging in the myocardium. J Mol Cell Cardiol 13, 471-488 (1981)
26. Messerli FH and Ketelhut R: Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol 17, 351-356 (1991)
27. Frohlich ED: Regression of cardiac hypertrophy and left ventricular pumping ability postregression. J Cardiovasc Pharmacol 17, Suppl 2, S81-S86 (1991)
28. Di Bello V, Pedrinelli R, Giorgi D, Bertini A, Talarico L, Caputo MT, Massimiliano B, Dell'Omo G, Paterni M and Giusti C: Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy. Athlete's heart and hypertension. Hypertension 29, 937-944 (1997)
29. Otterstad JE, Smiseth O and Kjeldsen SE: Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. Blood Press 5, 5-15 (1996)
30. Lièvre M, Guèret P, Gayet C, Roudaut R, Haugh MC, Delair S and Boissel J-P (on behalf of the HYCAR Study Group): Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 25, 92-97 (1995)
31. Schmieder RE, Martus P and Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275, 1507-1513 (1996)
32. Gohlke P and Unger T: Ramipril. In Cardiovascular Drug Therapy, 2nd Edition, Edited by Messerli F, pp 755-775, WB Saunders Company, Philadelphia (1996)
33. Agabiti-Rosei E and Muiesan ML: ACE-inhibitors and cardiovascular protection. Cardiologia 39, Suppl 1, 139-147 (1994)
34. Linz W, Schölkens BA and Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A11, 1325-1350 (1989)
35. Linz W, Wiemer G and Schölkens BA: Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens 11, Suppl 5, S96-S97 (1993)
36. Gohlke P, Stoll M, Lamberty V, Mattfeldt T, Mall G, Van Even P, Martorana PA and Unger Th: Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J Hypertens 10, Suppl 6, S141-S144 (1992)
37. Unger Th, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens and Gohlke P: Effect of early onset of ACE inhibition on myocardial capillaries in SHR. Hypertension 20, 478-482 (1992)
38. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A and Unger Th: Angiotensin converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23, 411-418 (1994)
39. Gohlke P, Kuwer I, Bartenbach S, Schnell A and Unger Th: Effect of low dose treatment with perindopril on cardiac function in stroke prone spontaneously hypertensive rats. Role of bradykinin. J Cardiovasc Pharmacol 24, 462-469 (1994)
40. Bao G, Gohlke P, Qadri F and Unger T: Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 20, 74-79 (1992)
41. Bao G, Gohlke P and Unger T: Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 20, Suppl 9, S96-S99 (1992)
42. Gohlke P, Kuwer I, Schnell A, Amann K, Makk G and Unger Th: Bradykinin B2-receptor blockade prevents the increase in capillary growth density induced by chronic ACE inhibitor treatment in SHRSP. Hypertension 29, 478-482 (1997)
43. Metsärinne KP, Stoll M, Gohlke P, Paul M and Unger Th: Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 2, 150-152 (1992)
44. Stoll M, Steckelings M, Paul M, Bottari SP, Metzger R and Unger Th: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95, 651-657 (1995)
45. Schölkens BA, Linz W and König W: Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by bradykinin antagonist. J Hypertens 6, Suppl 4, 25-28 (1988)
46. Mall G, Zimmer G, Baden S and Mattfeldt T: Capillary neoformation in the rat heart - stereological studies on papillary muscle in hypertrophy and physiologic heart. Basic Res Cardiol 85, 531-540 (1990)
47. Sharpe N, Smith H, Murphy J, Greaves S, Hart H and Gamble G: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet 337, 872-876 (1991)
48. Pfeffer MA, Lamas GA, Vaugham DE, Parisi AF and Braunwald E: Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 319, 80-86 (1988)
49. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH and Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327, 669-677 (1992)
50. The AIRE Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828 (1993)
51. Trandolapril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333, 1670-1676 (1995)
52. Martorana PA, Kettenbach B, Breipohl G, Linz W and Schölkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182, 395-396 (1990)
53. Stauss HM, Zhu Y-C, Redlich T, Adamiak D, Mott A, Kregel K and Unger Th: ACE inhibitors in infarct induced heart failure: bradykinin versus angiotensin II. J Cardiovasc Risk 1, 255-262 (1994)
54. Hartman JC, Hullinger TG, Wall MT and Shebuski RJ: Reduction of myocardial infarct size is independent of angiotensin II. Eur J Pharmacol 234, 229-236 (1993)
55. Spitznagel H, Stauss HM, Gohlke P, Zhu Y-Z, Zhu Y-C, Falkenhahn M and Unger T: Angiotensin II and bradykinin in hypertensive heart disease and myocardial infarction. High Blood Press 5, 119-123 (1996)
56. Ertl G: Angiotensin converting enzyme inhibitors and ischemic heart disease. Eur Heart J 9, 716-727 (1988)
57. Zhu Y-C, Stauss HM, Bao G, Gohlke P, Zhu Y-Z, Redlich Th and Unger Th: Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Can J Physiol Pharmacol 73, 827-831 (1995)
58. Linz W, Schölkens BA and Han YF: Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J Cardiovasc Pharmacol 8, Suppl 10, S91 -S99 (1986)
59. Linz W and Schölkens BA: Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J Cardiovasc Pharmacol 10, Suppl 7, S75-S82 (1987)
60. Pfeffer JM, Fisher TA and Pfeffer MA: Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 57, 805-826 (1995)
61. Falkenhahn M, Franke F, Bohle RM, Zhu Y-C, Stauss HM, Bachmann S, Danilov S and Unger Th: Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 25, 219-226 (1995)
62. Pfeffer MA and Braunwald E: Ventricular remodeling after myocardial infarction: experimental observation and clinical implications. Circulation 81, 771-772 (1990)
63. McDonald KM, Carlyle PF, Mathews J, Hauer K, Elbers T, Hunter D and Cohn JN: Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Physicians 103, 229-235 (1990)
64. Stauss HM, Zhu Y-C, Redlich T and Unger Th: Early and late treatment of infarction-induced heart failure with a converting enzyme inhibitor: bradykinin potentiation versus angiotensin II reduction. (Abstract) Hypertension 22, 429 (1993)
65. Grossman W and Lorell H: Hemodynamic aspects of left ventricular remodeling after myocardial infarction. Circulation 87, Suppl VII, 28-30 (1993)
66. Raya ET, Gay RG, Aguirre M and Goldman S: Importance of venodilation in prevention of left ventricular dilation after chronic myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 64, 330-337 (1989)
67. Schieffer B, Wriger A, Meybrunn M, Seitz S, Holtz T, Riede UN and Drexler H: Comparative effects of chronic angiotensin-converting enzyme inhibitor and angiotensin II Type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89, 2273-2282 (1994)
68. McDonald KM, Garr MD, Carlyle PF, Francis GF, Hauer K, Hunter DW, Parrish T, Stilman A and Cohn JN: The relative effects of alpha 1 adrenoceptor blockade, converting enzyme inhibitor therapy and angiotensin II subtype I receptor blockade on ventricular remodeling in the dogs. Circulation 90, 3024-3036 (1994)
69. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A and Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91, 2043-2048 (1995)